Irritable Bowel Drugs: Medications That Cause or Treat IBS

How IBS Is Classified Before Choosing a Drug

IBS drug selection depends entirely on the predominant bowel habit. The Rome IV criteria divide IBS into four subtypes: IBS with diarrhea (IBS-D), IBS with constipation (IBS-C), IBS with mixed bowel habits (IBS-M), and unsubtyped IBS. A clinician assigns the subtype based on the proportion of abnormal stool forms on the Bristol Stool Scale.

The 2021 American College of Gastroenterology (ACG) clinical guideline, published in the American Journal of Gastroenterology, provides the strongest evidence-based framework for IBS pharmacotherapy [1]. The guideline grades each recommendation by certainty of evidence and strength, which means not every approved drug carries the same endorsement. Subtyping matters because a drug that relieves IBS-D (like alosetron) can catastrophically worsen IBS-C.

Approximately 4.1 percent of the world population meets Rome IV criteria for IBS, though older Rome III estimates put the figure closer to 11 percent [2]. Women are diagnosed 1.5 to 2 times more often than men. The economic burden in the United States alone exceeds $1 billion annually in direct costs, not counting lost productivity [3].

Before any prescription, clinicians typically trial dietary modification (low-FODMAP diet), soluble fiber supplementation, and lifestyle changes. Drugs enter the picture when these measures fail or symptoms are moderate to severe.

FDA-Approved Drugs for IBS-D

Three drugs hold FDA approval specifically for IBS-D: rifaximin, eluxadoline, and alosetron. Each works through a different mechanism, and the choice depends on symptom severity, sex, and prior treatment history.

Rifaximin (Xifaxan). Rifaximin is a non-absorbed oral antibiotic dosed at 550 mg three times daily for 14 days. The TARGET 3 trial (N=2,438) demonstrated that 36 percent of rifaximin-treated patients achieved the composite endpoint of abdominal pain and stool consistency response, compared with 21 percent on placebo [4]. The ACG gives rifaximin a conditional recommendation based on moderate-quality evidence [1]. Repeat courses are permitted; the FDA label allows up to two retreatments.

Eluxadoline (Viberzi). Eluxadoline is a mixed mu-opioid receptor agonist and delta-opioid receptor antagonist dosed at 75 or 100 mg twice daily. In pooled phase 3 data (N=2,427), the 100 mg dose produced a composite response rate of 29.6 percent vs. 16.2 percent placebo at week 26 [5]. The drug is contraindicated in patients without a gallbladder because of an elevated risk of sphincter of Oddi spasm and pancreatitis. The ACG recommendation is conditional, with moderate certainty [1].

Alosetron (Lotronsa). Alosetron is a 5-HT3 receptor antagonist restricted to women with severe IBS-D who have not responded to conventional therapy. The restriction exists because of rare but serious ischemic colitis and severe constipation events. The starting dose is 0.5 mg twice daily. The ACG gives alosetron a conditional recommendation, noting low certainty of evidence for the risk-benefit balance [1].

Dr. Brian Lacy, a co-author of the ACG IBS guideline, has stated: "Rifaximin offers a unique advantage as a non-absorbed antibiotic that modifies the gut microbiome without systemic side effects, making it a reasonable first prescription choice for IBS-D patients who fail dietary therapy" [1].

FDA-Approved Drugs for IBS-C

Four prescription agents target IBS-C. All are secretagogues or prokinetics that increase intestinal fluid secretion or motility.

Linaclotide (Linzess). Linaclotide is a guanylate cyclase-C agonist dosed at 290 mcg once daily for IBS-C (a lower 72 mcg dose treats chronic idiopathic constipation). In a 12-week phase 3 trial (N=800), 33.7 percent of patients on 290 mcg met the FDA composite responder endpoint vs. 13.9 percent on placebo (P<0.001) [6]. The ACG gives linaclotide a strong recommendation with moderate certainty, the highest grade among IBS-C drugs [1]. Diarrhea is the most common adverse event, occurring in about 20 percent of patients. Taking the dose 30 minutes before breakfast reduces this risk.

Lubiprostone (Amitiza). Lubiprostone is a chloride channel activator dosed at 8 mcg twice daily for IBS-C. It is approved only for women aged 18 and older. A pooled analysis of two phase 3 trials (N=1,171) showed significantly higher overall responder rates with lubiprostone vs. placebo (17.9 vs. 10.1 percent) [7]. Nausea is the most frequent side effect, reported in approximately 8 percent of patients. The ACG offers a conditional recommendation with low certainty [1].

Plecanatide (Trulance). Plecanatide is another guanylate cyclase-C agonist dosed at 3 mg once daily. It mimics the endogenous peptide uroguanylin and activates in a pH-dependent manner in the proximal small intestine. In a 12-week trial (N=696), the overall responder rate was 30.2 percent vs. 17.8 percent for placebo (P<0.001) [8]. The ACG gives a conditional recommendation with moderate certainty [1].

Tegaserod (Zelnorm). Tegaserod is a 5-HT4 receptor agonist re-approved by the FDA in 2019 for women under 65 with IBS-C and no cardiovascular risk factors. Its original withdrawal in 2007 was due to cardiovascular safety signals, and the re-approval carries a narrow indication. The dose is 6 mg twice daily before meals [9].

Neuromodulators: Off-Label Drugs for IBS Pain

When abdominal pain dominates the clinical picture regardless of stool subtype, gut-brain neuromodulators are the next step. These are prescribed off-label.

Tricyclic antidepressants (TCAs). Low-dose amitriptyline (10 to 25 mg at bedtime) or nortriptyline is the most studied class. The ATLANTIS trial (N=463), published in The Lancet in 2023, found that low-dose amitriptyline produced a significant improvement in IBS Severity Scoring System scores at 6 months compared with placebo (adjusted difference: -27.0 points, 95% CI: -46.9 to -7.1) [10]. The ACG gives TCAs a conditional recommendation with low certainty, but the ATLANTIS data has since strengthened the evidence base considerably [1].

SSRIs. Fluoxetine (20 mg), citalopram, and paroxetine are sometimes used, particularly when anxiety or depression coexists. The evidence is weaker than for TCAs. A 2019 Cochrane review found that SSRIs improved global IBS symptoms compared with placebo (RR 0.68 to 95% CI 0.51 to 0.91), but the certainty of evidence was low [11]. The ACG suggests SSRIs only when TCAs fail or are not tolerated [1].

Antispasmodics. Hyoscyamine, dicyclomine, and peppermint oil act on smooth muscle to reduce cramping. The ACG recommends peppermint oil (conditional, low certainty) and notes that U.S.-available antispasmodics have limited high-quality trial data compared with European agents like otilonium and pinaverium [1].

Dr. Alexander Ford, lead author of the ATLANTIS trial and professor of gastroenterology at the University of Leeds, wrote: "Our findings support the use of low-dose amitriptyline as a second-line treatment for IBS in primary care, where most patients are managed" [10].

Common Drugs That Cause or Worsen IBS Symptoms

Several widely prescribed medications can trigger IBS-like symptoms or aggravate existing IBS. Identifying these drugs is a critical early step in any IBS evaluation.

NSAIDs. Ibuprofen, naproxen, and other non-steroidal anti-inflammatory drugs increase intestinal permeability by inhibiting cyclooxygenase-1 in the gut mucosa. A cross-sectional analysis of the Nurses' Health Study found that regular NSAID use was associated with a 1.59-fold increased odds of IBS (95% CI: 1.28 to 1.97) [12]. Patients with IBS should use acetaminophen as the default analgesic when possible.

Metformin. The most common first-line diabetes drug causes GI side effects in 20 to 30 percent of users. Diarrhea, bloating, and abdominal cramping overlap heavily with IBS-D symptoms. Extended-release formulations reduce but do not eliminate this risk. A 2017 meta-analysis confirmed dose-dependent GI adverse events with metformin [13].

Proton pump inhibitors (PPIs). Long-term PPI use alters the gut microbiome by raising gastric pH, which allows small intestinal bacterial overgrowth (SIBO). SIBO shares substantial symptom overlap with IBS. A 2020 systematic review found PPI use was associated with increased risk of SIBO (OR 1.71 to 95% CI: 1.20 to 2.43) [14].

Broad-spectrum antibiotics. Courses of amoxicillin-clavulanate, fluoroquinolones, and clindamycin disrupt the colonic microbiome and can produce post-infectious IBS (PI-IBS). A meta-analysis in Gut estimated that the risk of developing IBS after an episode of infectious gastroenteritis is roughly 11 percent, and antibiotic-associated dysbiosis likely contributes through a parallel mechanism [15].

Magnesium supplements. Magnesium citrate and magnesium oxide at doses above 400 mg daily exert an osmotic laxative effect and can worsen IBS-C patients' diarrhea during swing episodes or push IBS-M patients toward the diarrhea end.

Emerging Therapies and Pipeline Drugs

The IBS pipeline includes several mechanisms not yet represented among approved therapies.

Tenapanor (Ibsrela). Tenapanor is a sodium/hydrogen exchanger 3 (NHE3) inhibitor approved for IBS-C in 2019 at 50 mg twice daily. In the T3MPO-2 trial (N=593), the 12-week abdominal pain responder rate was 49.8 percent vs. 38.3 percent placebo [16]. It offers an alternative mechanism to guanylate cyclase-C agonists and may benefit patients who do not respond to linaclotide.

Olorinab. This full agonist of the cannabinoid receptor 2 (CB2) targets visceral pain without CNS psychoactive effects. Phase 2 data showed abdominal pain improvement in IBS patients with severe baseline pain, though phase 3 results are pending [17].

Gut-directed hypnotherapy. While not a drug, the ACG guideline gives gut-directed psychotherapies (cognitive behavioral therapy and gut-directed hypnotherapy) a conditional recommendation. A 2021 Lancet Gastroenterology & Hepatology trial (N=354) found that individual and group hypnotherapy were superior to educational supportive therapy at 12 months [18]. This positions psychotherapy as a genuine alternative, not a last resort.

Building a Treatment Algorithm: Which Drug First?

The ACG guideline does not prescribe a rigid stepwise algorithm, but clinical practice follows a general pattern based on the dominant symptom.

For IBS-D, the typical sequence begins with dietary modification (low-FODMAP) and loperamide for acute symptom control. If symptoms persist, rifaximin 550 mg three times daily for 14 days is the most common first prescription. Failure after two rifaximin courses leads to eluxadoline (if the gallbladder is intact) or a low-dose TCA. Alosetron is reserved for severe cases in women who have failed all other options.

For IBS-C, the standard sequence starts with soluble fiber (psyllium) and polyethylene glycol 3350 (an OTC osmotic laxative). The first prescription step is typically linaclotide 290 mcg or plecanatide 3 mg. Lubiprostone and tenapanor are alternatives when guanylate cyclase-C agonists are ineffective or produce intolerable diarrhea. Tegaserod occupies a narrow niche for younger women without cardiovascular risk.

For pain-predominant IBS of any subtype, low-dose amitriptyline (10 to 25 mg) is now the best-supported pharmacologic option after the ATLANTIS trial [10]. SSRIs are second-line. Antispasmodics provide short-term relief during flares but have limited long-term data.

A 2022 network meta-analysis in The Lancet Gastroenterology & Hepatology (N=18,123 across 75 trials) ranked alosetron, ramosetron, and rifaximin as the top three drugs for global IBS-D symptom improvement, while linaclotide ranked first for IBS-C [19]. These rankings align with the ACG recommendations but add granularity for shared decision-making.

Drug Safety: Monitoring and Red Flags

Most IBS drugs have favorable safety profiles, but specific monitoring points exist.

Alosetron requires enrollment in the Prometheus Risk Management Program. Prescribers must report serious adverse events, including ischemic colitis and complications of constipation. Patients should discontinue immediately if constipation or rectal bleeding develops [1].

Eluxadoline is contraindicated in patients who lack a gallbladder, have a history of pancreatitis, biliary duct obstruction, sphincter of Oddi dysfunction, or alcohol use disorder. Post-marketing reports documented cases of serious pancreatitis and death in cholecystectomized patients [20].

Linaclotide and plecanatide carry a boxed warning against use in patients under 6 years old due to deaths in neonatal mice from dehydration. They are also contraindicated in patients under 18 with known or suspected mechanical gastrointestinal obstruction.

TCAs at low doses rarely produce the cardiac or anticholinergic toxicity seen at antidepressant doses (150 to 300 mg), but baseline ECG is reasonable in patients over 65 or with known cardiac disease.

When to Escalate Beyond Standard Pharmacotherapy

Drug failure in IBS should prompt reassessment of the diagnosis. Alarm features that suggest something other than IBS include onset after age 50, unintentional weight loss exceeding 5 percent of body weight, nocturnal diarrhea that wakes the patient from sleep, rectal bleeding, iron deficiency anemia, and a family history of colorectal cancer or inflammatory bowel disease.

If alarm features are absent and two or more drug classes have failed, referral to a gastroenterologist with expertise in neurogastroenterology is appropriate. Anorectal physiology testing (for IBS-C), bile acid testing (SeHCAT scan or serum 7-alpha-hydroxy-4-cholesten-3-one, for IBS-D), and small bowel imaging may reveal treatable overlapping conditions such as bile acid diarrhea, pelvic floor dyssynergia, or SIBO.

The ACG guideline states that fecal microbiota transplantation for IBS should occur only in clinical trials, not routine practice [1]. Probiotics receive a conditional recommendation against their use, citing inconsistent strain-specific evidence.

Patients with refractory IBS-D should have celiac serologies checked if not already done, as celiac disease prevalence in IBS-D cohorts is roughly four times the general population rate of 1 percent.